Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2014 | Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

Jeffrey Matous • 6 Dec 2014
ASH 2014
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffrey Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.

More from Jeffrey Matous

The growing importance of bispecific antibodies in the treatment of multiple myeloma
1:47
The growing importance of bispecific antibodies in the treatment of multiple myeloma
Jeffrey Matous • 9 Dec 2024
Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1
3:41
Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1
Jeffrey Matous • 9 Dec 2024
An ongoing clinical trial investigating sonrotoclax in Waldenström’s macroglobulinemia
1:19
An ongoing clinical trial investigating sonrotoclax in Waldenström’s macroglobulinemia
Jeffrey Matous • 19 Oct 2024
A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM
1:04
A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM
Jeffrey Matous • 19 Oct 2024

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Jeffrey Matous • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Jeffrey Matous • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Jeffrey Matous • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Jeffrey Matous • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals